跳至主要内容
临床试验/NCT03829514
NCT03829514已完成4 期

Fenofibrate in Type 2 Diabetes- Novel Biomarkers and Mechanisms

Medical University of South Carolina1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2019年2月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
10
试验地点
1
主要终点
Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid Chromatography-mass Spectrometry

研究概览

简要总结

Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study will provide new clues as to how fenofibrate protects vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Type 2 diabetes of at least one year's duration; stable glycemic control (no more than 1.0% change in HbA1c in the previous six months, but no limit on HbA1c)
  • Triglycerides >150 mg/dL (in the previous six months)

排除标准

  • Previous use of Fenofibrate or other fibrates
  • Pregnancy
  • Active malignancy
  • Recent cardiac event or congestive heart failure
  • Active liver disease
  • Significant renal impairment (serum creatinine > 2mg/dl)

研究组 & 干预措施

Fenofibrate

Experimental

Single arm. Participants will take study medication

干预措施: Fenofibrate (Drug)

结局指标

主要结局

Number of Individual Plasma Proteins That Changed From Baseline to End-point Based on Limma T-Test of Protein Abundance as Determined by Proteomic Analysis Via Liquid Chromatography-mass Spectrometry

时间窗: Six weeks, from baseline visit to study completion visit

Protein exclusive intensity values (counts/second) were normalized using cyclic loess normalization. Mean protein abundance as determined by the intensity for each protein was determined. 95% confidence intervals were calculated as a measure of dispersion. Paired means were compared using a Limma T-test and the p-value was adjusted for multiple comparisons using the Benjamini-Hochberg method. Mean Log2 Fold Change was calculated for each protein compared between 6 weeks and baseline. The number of proteins that changed between 6 weeks and baseline was zero.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Timothy Lyons

Professor and Chief, Division of Endocrinology

Medical University of South Carolina

研究点 (1)

Loading locations...

相似试验

Fenofibrate in Type 2 Diabetes | 临床试验